PR-002

PR-002 is a small molecule therapeutic candidate being developed by Parkure for the treatment of Parkinson's disease. The compound was identified using Parkure's proprietary drug discovery platform, which utilizes *Drosophila* (fruit fly) models of Parkinson's disease to screen for small molecules that can rescue disease-related phenotypes, such as loss of dopaminergic neurons or locomotor defects. PR-002 is currently in the preclinical stage of development. While the specific molecular target of PR-002 has not been publicly disclosed, the program aims to provide disease-modifying effects for patients with Parkinson's disease by addressing underlying neurodegenerative processes identified in the company's screening models.